NeoChord
PrivateLast Round
Convertible Debt
Feb 27, 2025
Total Funding Raised
$70.59M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
NeoChord operates in Healthcare & Life Sciences and is based in Maple Grove, Minnesota. Its latest recorded funding round was a Convertible Debt round in February 2025.
NeoChord is a medical technology company that develops minimally invasive, beating-heart mitral valve repair tools for patients suffering from mitral valve regurgitation.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeoChord Comparables
Compare NeoChord with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Polares Medical | 89% | |
| HVR Cardio International | 88% | |
| CardioMech | 88% |
For institutional investors. Book with your work email.
NeoChord Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Feb 27, 2025 | ||||
| Series D Extension | Apr 23, 2019 | ||||
| Series D | Nov 5, 2018 | ||||
| Series C | Jun 9, 2015 | ||||
| Debt | Oct 24, 2013 | ||||
Debt | Sep 9, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NeoChord Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series D Extension, Series C, Series D |
| Square 1 Bank | Debt |
| Heron Capital | Series A, Series C, Series B |
| U.S. Venture Partners | Series D Extension, Series D |
| Baird Capital | Series C, Series D |
| Cedar Point Capital | Series A |
| Hopen Life Science Ventures | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 129% MoM, reaching 2.8K.
- Apr 23, 2019
$7M round led by Treo Ventures.
For institutional investors. Book with your work email.
NeoChord Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NeoChord's valuation, stock price, and market status.
Is NeoChord a public or private company?
NeoChord is a private company.
What is the current stock price of NeoChord?
NeoChord is a private company, so its shares have no public market price. Caplight tracks NeoChord's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NeoChord worth (valuation)?
Valuation information for NeoChord is not publicly available.
Can I buy NeoChord stock?
NeoChord shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NeoChord's last funding round?
NeoChord's most recent funding round was Convertible Debt on February 27, 2025.
Who are the main investors in NeoChord?
Key investors in NeoChord include Deerfield Management, U.S. Venture Partners, Treo Ventures.
Will NeoChord IPO soon?
No public IPO plans have been announced for NeoChord.
How can I track NeoChord secondary market activity?
Caplight tracks bids, offers, and trades in NeoChord's shares on secondary markets.